Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tosposertib - TiumBio/ Chiesi Farmaceutici

Next Previous
Drug Profile

Tosposertib - TiumBio/ Chiesi Farmaceutici

Alternative Names: NCE-401; Tosposertib-TiumBio/Chiesi Farmaceutici; TU-2218

Latest Information Update: 04 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TiumBio
  • Class 2 ring heterocyclic compounds; Antifibrotics; Antineoplastics; Imidazoles; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Transforming growth factor beta type I receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Squamous cell cancer
  • Phase I/II Solid tumours
  • No development reported Cancer; Idiopathic pulmonary fibrosis

Most Recent Events

  • 31 May 2026 Efficacy and adverse events data from a phase Ib/IIa trial in Solid tumours presented at the at American Society of Clinical Oncology (ASCO) 2026
  • 21 Nov 2025 Chemical structure information added.
  • 10 Nov 2025 Efficacy and adverse events data from a phase Ib/IIa trial in Solid tumours released by TiumBio

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top